华法林而非直接口服抗凝药或抗血小板治疗与急诊普外科患者围手术期出血风险增加相关:新型抗凝药时代的启示:一项EAST多中心研究
这项前瞻性观察性研究覆盖21个中心、2019至2022年,纳入413例在急诊普外科手术前24小时内使用抗血小板药、直接口服抗凝药或华法林的成人患者。使用华法林者围手术期出血并发症风险显著高于直接口服抗凝药使用者(OR 4.4,95%CI 2.0-9.9),校正混杂因素后为OR 6.3(95%CI 2.8-13.9);直接口服抗凝药组与抗血小板组的出血风险无显著差异(OR 0.7,95%CI 0.4-1.1)。华法林与死亡率无独立关联(校正OR 1.3,95%CI 0.39-4.7)。作者认为围手术期决策应由患者疾病与合并症决定,而非抗血小板或抗凝药物类型。
要点
- 急诊普外科术前24小时内使用华法林者,围手术期出血并发症的校正OR为6.3(95%CI 2.8-13.9),显著高于直接口服抗凝药使用者。
- 直接口服抗凝药与抗血小板药使用者的围手术期出血并发症无显著差异(OR 0.7,95%CI 0.4-1.1)。
- 华法林与死亡率无独立关联(校正OR 1.3,95%CI 0.39-4.7),术中血管加压药使用(OR 4.7,95%CI 1.7-12.8)和术后出血(OR 5.5,95%CI 2.4-12.8)与死亡率独立相关。
- 未校正分析中,华法林较直接口服抗凝药的围手术期出血并发症OR为4.4(95%CI 2.0-9.9)。
- 作者认为围手术期决策应依据患者疾病与合并症,而非抗血小板或抗凝药物类型。
适用人群与场景
- 年龄18岁及以上、需行急诊普外科手术且在术前24小时内使用过直接口服抗凝药、华法林或抗血小板药物的患者。
- 急诊普外科手术场景,2019至2022年21个中心的前瞻性观察性研究人群。
研究设计与关键结果
- 研究类型为前瞻性观察性研究,覆盖21个中心,2019至2022年,共纳入413例患者。
- 413例中,抗血小板药使用者221例(53.5%),直接口服抗凝药使用者152例(36.8%),华法林使用者40例(9.7%)。
- 手术指征最常见为梗阻(抗血小板组23%、直接口服抗凝药组45%、华法林组28%)、肠缺血(13%、17%、23%)、憩室炎/消化性溃疡(7%、7%、15%)。
- 与直接口服抗凝药相比,华法林与显著更高的围手术期出血并发症相关(OR 4.4,95%CI 2.0-9.9);直接口服抗凝药与抗血小板药的围手术期出血并发症无显著差异(OR 0.7,95%CI 0.4-1.1)。
- 与直接口服抗凝药相比,华法林(OR 0.7,95%CI 0.2-2.5)或抗血小板药(OR 0.5,95%CI 0.2-1.2)的死亡率无显著差异。
- 校正混杂因素后,华法林(OR 6.3,95%CI 2.8-13.9)、病史和手术指征与围手术期出血并发症增加相关。
- 校正混杂因素后,华法林与死亡风险无独立关联(OR 1.3,95%CI 0.39-4.7),而术中血管加压药使用(OR 4.7,95%CI 1.7-12.8)、病史和术后出血(OR 5.5,95%CI 2.4-12.8)与死亡风险相关。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究;证据等级:预后与流行病学,Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,围手术期决策应依据患者疾病与合并症,而非抗血小板或抗凝药物类型。
- 本研究提示华法林而非直接口服抗凝药与更高的围手术期出血并发症相关,但该风险未导致死亡率增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: This study aimed to assess perioperative bleeding complications and in-hospital mortality in patients requiring emergency general surgery presenting with a history of antiplatelet (AP) versus direct oral anticoagulant (DOAC) versus warfarin use.
METHODS: A prospective observational study across 21 centers between 2019 and 2022 was conducted. Inclusion criteria were age 18 years or older, and DOAC, warfarin, or AP use within 24 hours of an emergency general surgery procedure. Outcomes included perioperative bleeding and in-hospital mortality. The study was conducted using analysis of variance, χ 2 , and multivariable regression models.
RESULTS: Of the 413 patients, 221 (53.5%) reported AP use, 152 (36.8%) DOAC use, and 40 (9.7%) warfarin use. The most common indications for surgery were obstruction (23% [AP], 45% [DOAC], and 28% [warfarin]), intestinal ischemia (13%, 17%, and 23%), and diverticulitis/peptic ulcers (7%, 7%, and 15%). Compared with DOAC use, warfarin use was associated with significantly higher perioperative bleeding complication (odds ratio [OR], 4.4 [95% confidence interval (CI), 2.0-9.9]). There was no significant difference in perioperative bleeding complication between DOAC and AP use (OR, 0.7 [95% CI, 0.4-1.1]). Compared with DOAC use, there was no significant difference in mortality between warfarin use (OR, 0.7 [95% CI, 0.2-2.5]) or AP use (OR, 0.5 [95% CI, 0.2-1.2]). After adjusting for confounders, warfarin use (OR, 6.3 [95% CI, 2.8-13.9]), medical history, and operative indication were associated with an increase in perioperative bleeding complications. However, warfarin was not independently associated with risk of mortality (OR, 1.3 [95% CI, 0.39-4.7]), whereas intraoperative vasopressor use (OR, 4.7 [95% CI, 1.7-12.8]), medical history, and postoperative bleeding (OR, 5.5 [95% CI, 2.4-12.8]) were.
CONCLUSION: Despite ongoing concerns about the increase in DOAC use and lack of readily available reversal agents, this study suggests that warfarin, rather than DOACs, is associated with higher perioperative bleeding complications. However, that risk does not result in an increase in mortality, suggesting that perioperative decisions should be dictated by patient disease and comorbidities rather than type of AP or anticoagulant use.
LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level III.
参考来源
- Anandalwar SP, O'Meara L, Vesselinov R, et al. Warfarin, not direct oral anticoagulants or antiplatelet therapy, is associated with increased bleeding risk in emergency general surgery patients: Implications in this new era of novel anticoagulants: An EAST multicenter study. J Trauma Acute Care Surg. 2024. PMID: 38595274. doi:10.1097/TA.0000000000004278
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。